Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Why did Trump impose 50% tariffs on Brazil? How did Nvidia reach a $4 trillion valuation? Why is X CEO Linda Yaccarino stepping down? What impact could Trump's copper tariffs have? How are Trump’s tariffs affecting US trade? Why is OpenAI launching an AI-powered browser? What caused WK Kellogg's stock to jump 50%?

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

benzinga.com/news/health-care/25/07/46325593/gileads-lenacapavir-plan-faces-global-hurdles-as-it-commits-to-no-profit-access-for-2-million

Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis…

This story appeared on benzinga.com, 2025-07-09 16:40:33.